Literature DB >> 3849978

Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma.

J D Gangemi, G N Olsen, C Fechter, J A Hightower, C T Bauguess, L Krech.   

Abstract

Human bronchoalveolar cells were obtained by lavage during diagnostic fiberoptic bronchoscopy of 21 patients suspected of having lung malignancies. Of these patients 11 were diagnosed as having primary lung cancer (Group I) and included individuals with squamous cell carcinoma, adenocarcinoma, undifferentiated large and oat cell carcinoma at varying locations and TNM stages, 4 patients demonstrated nonprimary metastatic carcinoma (Group II), and 6 patients did not reveal detectable tumors by bronchoscopy or follow-up (Group III) and were included as study controls. We examined the ability of pulmonary alveolar macrophages (PAMs) lavaged from patients in each of the three study groups to phagocytose opsonized sheep red blood cells. Phagocytic activity varied among patients in the same and different study groups; however, no significant differences were observed in the phagocytic or tumoristatic activities of PAMs recovered from tumor-bearing and nontumor-bearing lung regions of the same patient. Moreover, lavage fluids collected from tumor-bearing regions did not suppress the phagocytic activity of PAMs collected from control lungs nor lung regions contralateral to the tumor-bearing lung. The data do not support the view that bronchial neoplasms or their secreted products suppress phagocytic functions of alveolar macrophages.

Entities:  

Mesh:

Year:  1985        PMID: 3849978     DOI: 10.1007/bf00205683

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Destruction of tumor cells by BCG-activated alqolar macrophages.

Authors:  B S Zwilling; L B Campolito
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  Pulmonary alveolar macrophage chemotaxis in malignant tumors of the lung.

Authors:  G Renoux; E Lemarie; M F Legrand; M Renoux; M Lavandier
Journal:  Adv Exp Med Biol       Date:  1982       Impact factor: 2.622

3.  Sample size nomograms for interpreting negative clinical studies.

Authors:  M J Young; E A Bresnitz; B L Strom
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

4.  Human pulmonary macrophages. Pinocytic activity in bronchial carcinoma and in the presence of levamisole and cyclosporin A.

Authors:  P N Plowman
Journal:  Clin Oncol       Date:  1982-03

5.  Human pulmonary macrophage tumor cell cytotoxicity.

Authors:  P Lemarbre; J Hoidal; R Vesella; J Rinehart
Journal:  Blood       Date:  1980-04       Impact factor: 22.113

6.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

7.  Case for using only maximum diameter in measuring tumors.

Authors:  J Gurland; R O Johnson
Journal:  Cancer Chemother Rep       Date:  1966-03

8.  Cytotoxicity on tumour cells of human mononuclear phagocytes: defective tumoricidal capacity of alveolar macrophages.

Authors:  C Bordignon; R Avallone; G Peri; N Polentarutti; C Mangioni; A Mantovani
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

9.  Human macrophage function in cancer: systemic and local changes detected by an assay for Fc receptor expression.

Authors:  J Rhodes; P Plowman; M Bishop; D Lipscomb
Journal:  J Natl Cancer Inst       Date:  1981-03       Impact factor: 13.506

10.  Human bronchoalveolar macrophage cytotoxicity for cultured human lung-tumour cells.

Authors:  S Swinburne; M Moore; P Cole
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

View more
  1 in total

1.  Alveolar macrophage function is altered in patients with lung cancer.

Authors:  D S Pouniotis; M Plebanski; V Apostolopoulos; C F McDonald
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.